English 
Español
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Related Articles
-
UDIBI
Published: april 2nd, 2020 Development and Evaluation of a Set of Spike and Receptor Binding Domain‐Based Enzyme‐Linked Immunosorbent Assays...
-
UDIBI
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody. SHOW MORE
-
UDIBI
Determination of Peptide Profile Consistency and Safety of Collagen Hydrolysates as Quality Attributes. SHOW MORE
-
-
UDIBI
Characterization of a Complex Mixture of Immunomodulator Peptides Obtained from Autologous Urine. SHOW MORE
-
UDIBI
Published: September 6, 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a...
-
UDIBI
Published: march 20, 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear magnetic resonance spectroscopy More...
-
UDIBI
Published: February 27, 2023 Discovery and Optimization of Neutralizing SARS-CoV-2 Antibodies Using ALTHEA Gold Plus Libraries™ More information
